MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts

K Rao-Bindal, Z Zhou and ES Kleinerman*

Fas expression is inversely correlated with the metastatic potential of osteosarcoma (OS) cells to the lungs. Fas$^+$ cells are rapidly eliminated when they enter the lungs via their interaction with constitutive Fas ligand (FasL) on the lung epithelium, whereas Fas$^-$ OS cells escape this FasL-induced apoptosis and survive in the lung microenvironment. Uptregulation of Fas expression in established OS lung metastases results in tumor regression. Here, we demonstrate that treatment of Fas$^-$ OS cells with the histone deacetylase inhibitor MS-275 results in the upregulation of Fas mRNA and sensitizes these cells to FasL-induced apoptosis. However, flow cytometry analysis revealed that Fas cell surface protein expression was not significantly increased. Rather, we observed increased levels of Fas within the membrane lipid rafts, as demonstrated by an increase in Fas expression in detergent-insoluble lipid raft fractions and colocalization with GM1$^+$ lipid rafts. We had previously shown that MS-275 treatment inhibited expression of the anti-apoptotic cellular FLICE-inhibitory protein (c-FLIP). Here, we demonstrated that transfection of cells with short hairpin RNA to c-FLIP also resulted in the localization of Fas to lipid rafts. Overall, our studies indicate that MS-275 sensitizes OS cells to FasL by upregulating the expression of Fas in membrane lipid rafts, which correlates with the c-FLIP-dependent distribution of Fas to lipid rafts.

Received 06.2.12; revised 25.6.12; accepted 26.6.12; Edited by A Stephanou
affecting gene transcription. Although several groups have identified probable mechanisms of HDAC inhibitor cytotoxicity, the effect of these drugs on the Fas pathway, particularly in OS, is not well understood. Blocking the Fas pathway by introducing dominant-negative FADD abrogated this effect. This result suggests that the Fas signaling pathway has a role in the ability of MS-275 to sensitize cells to FasL-induced apoptosis. One way to enhance cell sensitivity to FasL is to upregulate the expression of the Fas receptor. Here, we report that MS-275 upregulates the expression of Fas mRNA and protein and induces the redistribution of Fas to membrane lipid rafts. We have also demonstrated that MS-275 decreases c-FLIP expression in OS cells. In this study, we demonstrate that the downregulation of c-FLIP alone also leads to the redistribution of Fas to lipid rafts and sensitizes cells to FasL. Our findings indicate that therapeutic agents that increase Fas localization to lipid rafts or those that decrease c-FLIP expression may be useful in sensitizing OS cells to FasL-induced apoptosis.

Results

MS-275 sensitizes Fas− OS cells to FasL-induced apoptosis. The cytotoxic effects of MS-275 were quantified using human OS cell lines LM7 and CCH-OS-D. Both cell lines express low levels of Fas and are highly metastastic when injected into nude mice. As expected, these cells were not sensitive to soluble FasL (sFasL) alone (Figure 1). By contrast, treatment of cells with MS-275 increased cell sensitivity to sFasL (Figure 1). Cytotoxic levels in cells treated with both MS-275 and sFasL were higher than those treated with MS-275 alone.

Increased Fas mRNA and protein facilitates FasL binding following treatment of OS cells with MS-275. HDAC inhibitors act on histone acetylation to regulate gene expression. We therefore sought to determine whether MS-275 induced a change in Fas expression in LM7 and CCH-OS-D cells. Following treatment of both cell lines with MS-275, there was an increase in Fas mRNA that peaked at 24 h after addition of MS-275 (Table 1). There was also an increase in Fas protein expression that was time dependent (Figure 2a). In contrast, the cell surface expression of Fas, as detected by flow cytometry, did not change after addition of MS-275 (Figure 2b). However, MS-275 treatment did result in a significant increase in sFasL binding (Figure 2b). These results suggest that the increased Fas protein induced by MS-275 may be in specific membrane compartments not detectable by flow cytometry.

Lipid rafts are required for MS-275-induced sensitization to FasL. Recent studies have demonstrated the importance of membrane lipid raft platforms in Fas receptor signaling. To determine whether there was increased Fas expression in the lipid rafts following MS-275 treatment, we performed sucrose gradient density centrifugation to extract the lipid rafts. The cholesterol content was increased in fractions 3–6, confirming the presence of lipid rafts in these fractions (Figure 3a). Western blot analysis with an antibody against the lipid raft marker, cholera toxin B subunit (CTxB)-GM1, confirmed that fractions 3–6 contained lipid raft proteins, whereas fractions 7–9 contained non-raft proteins as determined by transferrin receptor expression, a protein that is excluded from lipid rafts (Figure 3b). Compared with untreated control cells, cells treated with MS-275 displayed increased Fas expression in the lipid raft fractions (Figure 3b). These results suggest that the increase in Fas protein induced after MS-275 treatment was in lipid raft

Table 1 MS-275 increases Fas mRNA expression

| Treatment   | Fas mRNA expression (fold increase) |
|-------------|------------------------------------|
|             | LM7                  | CCH-OS-D                      |
| Untreated   | 1                    | 1                              |
| MS-275 12h | 2.3 ± 0.85            | 1.9 ± 0.82                    |
| MS-275 24h | 7.2 ± 1.49            | 3.3 ± 0.76                    |
| MS-275 48h | 3.4 ± 0.93            | 1.5 ± 0.3                     |

Abbreviation: OS, osteosarcoma. OS cells were treated with 2 μM MS-275 for 24 h. RNA was isolated from cells using Trizol reagent, and quantitative real-time PCR was performed using primers specific for Fas. Data show the average and S.D. of five independent experiments.

Figure 1 MS-275 sensitizes OS cells to FasL-induced apoptosis. LM7 and CCH-OS-D cells were treated with sFasL for 24 h, 2 μM MS-275 for 48 h, or both. The percentage of apoptotic cells was determined using the acridine orange/ethidium bromide staining assay. Stained cells were visualized using a fluorescent microscope, and apoptosis was determined as the percentage of apoptotic cells out of 100 counted cells. The average and S.D. of three independent experiments is shown. For MS-275 versus MS-275 and sFasL in combination, $P = 0.02$ and $P = 0.01$ for LM7 and CCH-OS-D, respectively.
microdomains rather than the non-raft regions of the cell surface.

To further confirm the localization of Fas, immunofluorescence staining of Fas and CTx-B-GM1 was performed. Untreated cells had low levels of Fas expression localized outside of lipid rafts, whereas cells treated with MS-275 had significantly increased colocalization of Fas within GM1⁺ lipid rafts (Figures 3c and d), confirming our results from the fractionation studies.

If localization of Fas in lipid rafts is required for MS-275-induced sensitization of cells to sFasL, then inhibiting lipid raft formation should abrogate this effect. To test this hypothesis, the cholesterol sequester methyl-β-cyclodextrin (MβCD) was used to deplete cholesterol and inhibit lipid raft formation in the cells before treatment with MS-275. Reduced cholesterol content was confirmed (Figure 4a). Cells were then treated with MS-275, sFasL, or both and the cytotoxicity was assessed using a clonogenic assay. As anticipated, pretreatment of cells with MβCD reduced both the cholesterol content and the cytotoxicity associated with the combination of MS-275 and sFasL (Figures 4a, b and c). These results suggest that Fas distribution in the lipid rafts is required for MS-275-induced sensitization to sFasL.

**c-FLIP regulates the localization of Fas in lipid rafts.** We previously demonstrated that MS-275 downregulates c-FLIP expression in OS cells and in OS lung metastases following oral administration of MS-275. We therefore investigated whether the MS-275-induced redistribution of Fas to the lipid rafts was mediated by an effect on c-FLIP. Cells with decreased c-FLIP expression were generated by transfection of cells with short hairpin RNA (shRNA) to c-FLIP. Quantitative real-time PCR and western blot analysis confirmed a significant decrease in c-FLIP expression following transfection with shRNA (Figures 5a and b). Fas expression in lipid raft and non-raft fractions was then investigated. Inhibiting c-FLIP increased Fas expression in lipid raft fractions compared with control sh-scrambled-transfected cells (Figure 5c). Amplex red assay was used to confirm separation of lipid raft fractions (Figure 5d).
Further, the inhibition of c-FLIP increased the colocalization of Fas in GM1^+ lipid rafts (Figure 5e). These studies indicate that inhibition of c-FLIP can enhance the expression of Fas in lipid raft regions.

**Discussion**

Accumulating evidence suggests that downregulation of Fas or corruption of the Fas signaling pathway has a critical role in the formation of OS lung metastases. In contrast to primary tumors, which contain a mixed population of Fas^+ and Fas^- cells, OS lung metastases are Fas^-7 As the lung is one of the few organs to expresses Fasl, this implicates the role of the lung microenvironment in the elimination of the Fas^- OS cells, leaving only Fas^+ cells to form metastases. Indeed, we have shown that Fas^- OS cells are rapidly cleared from the lung while Fas^+ cells remain.19 In addition, we previously showed that the upregulation of Fas in established Fas^- OS lung metastases results in tumor regression.22 Therefore, agents that increase Fas expression may have therapeutic potential for patients with OS lung metastases.

Initial studies demonstrated that selective inhibition of HDAC-1 or HDAC-3 resulted in the upregulation of Fas mRNA in OS cells.23,24 Here, we showed that MS-275, an HDAC 1/3-specific inhibitor, sensitized Fas^- OS cells to FasL-induced cell death. We also demonstrated that treatment of cells with MS-275 upregulated Fas mRNA and protein levels. However, flow cytometry was unable to demonstrate an increase in Fas expression on the cell surface. Interestingly, treatment of cells with MS-275 increased binding to sFasL, which suggested an enhanced availability of Fas receptor on the cell membrane and that Fas may be localized to specific membrane compartments. Much of the recent focus in death receptor signaling has been on the importance of lipid rafts as platforms for Fas receptor signaling.11–14 Our results provide the first evidence that treatment of OS cells with an HDAC inhibitor results in increased localization of the Fas receptor in lipid raft
Figure 4  Lipid rafts are required for MS-275-induced sensitization to FasL. LM7 and CCH-OS-D cells were pretreated with 20 μM MjCD for 1 h and then treated with 2 μM MS-275 for 48 h, sFasL for 24 h, or both. (a) Cholesterol content following MjCD treatment was measured using the Amplex red assay. (b) Cytotoxicity with or without MjCD was assessed using a clonogenic assay. (c) Quantified number of colonies of four independent experiments. Data show average and S.D.
microdomains, as revealed by our analysis of sucrose gradient fractionation and enhanced colocalization of Fas with GM1⁺ lipid rafts. These findings are supported by our observation that disruption of lipid rafts with the cholesterol sequester MβCD abrogated the ability of MS-275 to sensitize OS cells to sFasL.

Death-receptor-induced apoptosis is inhibited by c-FLIP, and overexpression of c-FLIP can confer resistance to Fas-mediated apoptosis.25–29 We previously demonstrated that MS-275 treatment results in the downregulation of c-FLIP mRNA and protein in OS cells.16 In addition, oral administration of MS-275 in mice with established OS pulmonary metastases decreased c-FLIP protein levels in tumors.16 c-FLIP has recently been shown to regulate the distribution of the death receptors DR4 and DR5 in lipid rafts.30 We therefore investigated whether altering c-FLIP would affect the localization of Fas in lipid rafts. Using shRNA transfection to inhibit c-FLIP expression, we demonstrated that downregulation of

Figure 5  Inhibition of c-FLIP increases localization of Fas in lipid rafts. (a and b) Expression of c-FLIP mRNA and protein was determined by quantitative real-time PCR and western blot, respectively, in cells transfected with empty vector (negative control), sh-scrambled clones, and shFLIP-knockdown clones. (c) Cells were lysed with Triton X-100 and lysates subjected to sucrose density gradient centrifugation. Each gradient fraction was analyzed by western blotting for Fas, CTxB-GM1, and transferrin receptor (TfR). (d) Amplex red assay was used to confirm higher cholesterol content in fractions 3–6. Data are representative of three independent experiments. (e) Immunofluorescence staining was performed using anti-CTxB-GM1 Alexa Fluor 594 antibody or anti-Fas antibody followed by anti-mouse Alexa Fluor 488 antibody. Areas of yellow represent colocalization.
c-FLIP in OS cells increased Fas localization in GM1 lipid rafts. Our findings suggest a novel role for c-FLIP in mediating the Fas-specific distribution in lipid rafts as well as the mechanism by which MS-275 increases the localization of Fas to the lipid rafts and sensitizes OS cells to FasL.

There is an ongoing need for novel therapeutic strategies for patients with OS lung metastases. Overall, we demonstrated that the HDAC inhibitor MS-275 sensitizes OS cells to FasL-induced cell death by increasing the expression of Fas in lipid raft microdomains, which correlates with c-FLIP downregulation. Oral MS-275 administered to mice with OS lung metastases resulted in decreased c-FLIP in the tumor nodules and tumor regression.10 Thus, modulating Fas distribution in lipid rafts by inhibiting c-FLIP may be a novel therapeutic strategy for treating OS lung metastases cells that have lost Fas expression. Upregulating the Fas expression in the lipid rafts may induce tumor susceptibility to the FasL- lung microenvironment. This is an example of how the tumor microenvironment can be harnessed to eradicate metastatic cells. Therapeutic strategies aimed at altering tumor Fas expression may therefore have a role in the treatment of metastatic OS in the lungs.

Materials and Methods

Cell lines and reagents. Human OS LM7 and CCH-OS-D cells were maintained in complete Dulbecco’s modified Eagle’s medium (Whittaker Bioproducts Inc., Walkersville, MD, USA) supplemented with 10% heat-inactivated bovine serum (Intergen, Purchase, NY, USA). The LM7 cells were derived from SAOS-2 cells in our laboratory by recycling through the lungs of nude mice.17 CCH-OS-D cells were a kind gift from Dennis Hughes, MD, PhD (Division of Pediatrics, The University of Texas MD Anderson Cancer Center). All cell lines were mycoplasma-negative and validated by short tandem repeat DNA Fingerprinting using the AmpFLSTR Identifier kit (Applied Biosystems, Carlsbad, CA, USA). The authenticity of cells was determined by the Characterized Cell Line Core at The University of Texas MD Anderson Cancer Center. Super FasL (human recombinant sFasL) was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). MS-275 was a generous gift from Syndax Pharmaceuticals, Inc. (Walihm, MA, USA). The lipid raft-inhibiting agent M/ICD was purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA).

Cytotoxicity and apoptosis assays. Clonogenic assays were performed to assess the cytotoxicity of OS cells after the addition of 10 ng/ml sFasL for 24 h, 2 µM MS-275 for 48 h, or both. Cells were pretreated with M/ICD for 1 h. The medium was then removed, and the cells were allowed to grow for 12 days, washed with PBS, and fixed with formalin. Cells were then stained with 0.4% crystal violet for 30 min, and colonies were counted. Clonogenic assays were performed in triplicate. The acridine orange/ethidium bromide assay was used to measure apoptosis. Cells were plated in 4-well slides and treated with 10 ng/ml sFasL for 24 h, 2 µM MS-275 for 48 h, or both. The conventional acridine orange/ethidium bromide staining protocol was performed following the guidelines from Current Protocols of Immunology.31,32 Briefly, a fluorescent acridine orange/ethidium bromide dye mix, containing 100 µg/ml acridine orange (Sigma-Aldrich, Inc.) and 100 µg/ml ethidium bromide (Sigma-Aldrich, Inc.), was added to each well and the cells were visualized using a fluorescent microscope. Apoptosis was determined as the percentage of apoptotic cells out of all counted cells. The assay was performed in triplicate, and data were averaged.

Flow cytometry and ligand-binding assay. One million OS cells were suspended in FACS buffer (PBS, containing 2% fetal calf serum and 0.1% sodium azide) and incubated with either 1.0 mg/ml PE-conjugated mouse anti-human Fas antibody or anti-human FLAG antibody (ProZyme, Hayward, CA, USA) to detect Fas and FasL expression, respectively. PE-conjugated isotype-control IgG antibodies were used as negative controls. Samples were analyzed using a FACSScan (Becton Dickinson, Mountain View, CA, USA).

Quantitative real-time PCR. Total RNA was isolated from OS cells using Trizol reagent (Life Technologies, Inc., Gaitherburg, MD, USA). RNA was then reverse transcribed using a Reverse Transcription System (Promega Co., Madison, WI, USA). The resulting cDNA was used for PCR amplification with SYBR green buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and specific primers for Fas (5’-GGCATTAGTCACCTTTGAATGA-3’ and 5’-GACCATTACTCAGGACCAAG-3’). Primers for β-actin were used as controls. Quantitative real-time PCR was performed in triplicate using the Bio-Rad iCycler iQ detection system. Cycling conditions were 95 °C for 3 min, 45 cycles of 59 °C annealing for 30 s, 95 °C for 30 s, and 60 °C for 1 min.

Western blotting and antibodies. OS cells were collected and lysed using NP-40 buffer (for Fas) or radioimmunoprecipitation buffer (for c-FLIP). Equal amounts of protein were separated on a 10% SDS-PAGE gel and blotted to the nitrocellulose membrane (Amerham Biosciences Corp., Piscatway, NJ, USA). The membranes were blocked with 5% non-fat dry milk in PBS containing 0.1% Tween-20 and then incubated with either anti-Fas antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-FLIP antibody (NF6, Enzo Life Sciences, Inc.) according to the manufacturer’s instructions.

Immunofluorescence staining. LM7 and CCH-OS-D cells were cultured in 4-well chamber slides and were either untreated or treated with 2 µM MS-275 for 48 h. Cells were fixed with 4% paraformaldehyde in PBS for 30 min. Samples were then incubated with anti-CTXb antibody conjugated to Alexa Fluor 594 (Molecular Probes, Eugene, OR, USA) at 4 °C overnight. After washing three times with PBS, the samples were incubated with anti-Fas antibody (BD Biosciences, Franklin Lakes, NJ, USA) at 4 °C overnight, followed by anti-mouse Alexa Fluor 488 antibody (Jackson Immunoresearch, West Grove, PA, USA) at 37 °C for 2 h. After being washed with PBS, the samples were mounted and visualized with a fluorescent microscope. The colocalization of CTXb- and Fas-positive areas (yellow area) were quantified by the Simple PCI software (Hamamastu, Bridgewater, NJ, USA) in five random fields. The average relative expression and S.E. was calculated from the data in MS-275-treated and -untreated cells.

Generation of c-FLIP shRNA-expressing clones. To stably knock down c-FLIP expression, OS cells were transduced with retroviruses-expressing shRNA-c-FLIP, shRNA-scrambled, or vector pGFP-V-RS (Origene Technologies, Inc., Rockville, MD, USA). Cells were grown in medium containing puromycin to select for stably transfected clones. shRNA constructs were tested for knockdown using western blot analysis with an antibody against c-FLIP (NF6) and by quantitative real-time-PCR using primers against c-FLIP (5’-ACGGAGACTACGACAGTCTTGTG-3’ and 5’-CAATGTGAAGATCCAGGAGTGGG-3’). The pGFP-V-RS vector containing the 29-mer shRNA sequence 5’-TGCAACATGGTCCAGAAGGCAGTACT-3’ (ID: GI55835) exhibited >80% c-FLIP knockdown.

Lipid raft fractionation and cholesterol assays. Lipid raft fractions were isolated using the Caveola/Rafts isolation kit (Sigma-Aldrich, Inc.) performed according to the manufacturer’s instructions. Briefly, samples were centrifuged and the pellet was extracted with lysis buffer containing 1% Triton X-100 and incubated on ice for 30 min. Lysates were mixed with cold OptiPrep density gradient medium and then overlaid with 35, 30, 25, 20, or 0% OptiPrep in an ultracentrifuge tube. Samples were then centrifuged at 200,000 g for 4 h at 4 °C. Nine 1-ml fractions were collected from the top to the bottom of each tube. Western blotting was performed with antibodies against Fas (Santa Cruz Biotechnology), HRP-conjugated CTXb (Sigma-Aldrich, Inc.) as a lipid raft marker, or transferrin receptor (Invitrogen Corporation, Carlsbad, CA, USA) as control. An Amplicor red assay kit was used to measure the cholesterol content in samples according to the manufacturer’s protocol (Invitrogen Corporation).

Statistical analysis. Statistical comparisons of groups were performed using student t-test using the GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA) program. A P-value of <0.05 was deemed as statistically significant.

Conflict of Interest

The authors declare no conflict of interest.
Acknowledgements. This work was supported by the National Cancer Institute grant R01 CA42992 (ESK) and the National Institutes of Health core grant CA16672 (ESK), and in part by a fellowship award from the American Legion Auxiliary (KR-B). We thank Dr. Peter Ordentlich and Syndax Pharmaceuticals, Inc. for contributing the MS-275 compound used in our studies. We also acknowledge Dr. Nadezhda V Koshkina for her helpful suggestions. This paper includes data that was presented in a dissertation (by KR-B) to The University of Texas MD Anderson Cancer Center and UT Health Graduate School of Biomedical Sciences: Bindal, Krithi R. "The histone deacetylase inhibitor, MS-275, sensitizes metastatic osteosarcoma to FasL-induced cell death: a role for c-FLIP" (2012). UT GSGS Dissertations and Theses. Paper 218.

1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178.
2. French LE, Hahn M, Ward I, Radigruber G, Zanone R, Becker K et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 333–343.
3. Worth LL, Leflure EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002; 9: 833–837.
4. Giuliano AE, Feig S, Elber FR. Changing metastatic patterns of osteosarcoma. Cancer 1984; 54: 2160–2164.
5. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethyleneimine vector. Cancer Gene Ther 2002; 9: 269–266.
6. Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 2010; 23: 189–196.
7. Gordon N, Koshkina NV, Jia SF, Mendoza A, Worth LL et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007; 13: 4503–4510.
8. Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 2003; 9: 3462–3468.
9. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296: 1635–1636.
10. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. Palmitoylation is required for efficient Fas cell death signaling. EMBO J 2002; 21: 3704–3714.
11. Grassme H, Jekle A, Riehle A, Schwartz H, Berger J, Sandhoff K et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001; 276: 20589–20596.
12. Chakrabandhu K, Heirons Z, Huault S, Dost B, Peng L, Conchaoud F et al. Palmitoylation is required for efficient Fas cell death signaling. EMBO J 2002; 21: 209–220.
13. Chainge-Delalande B, Moreau JF, Legembre P. Rewinding the DISC. Cell Death and Disease 2008; 5: 9–14.
14. Bionda C, Althias A, Poncet D, Alphsone G, Guezouza A, Gambert P et al. Differential regulation of cell death in head and neck cell carcinoma through alteration of cholesterol levels in lipid rafts microdomains. Biochem Pharmacol 2008; 75: 761–772.
15. Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNX-276 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011; 117: 3457–3467.
16. Rao-Bindal K, Kleinerman ES. The histone deacetylase inhibitor, MS-275, sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, Orlando Florida: Philadelphia (PA): AACR 2011 April 2–5.
17. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999; 17: 501–506.
18. Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Rev 2009; 35: 497–508.
19. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs; the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007; 5: 991–999.
20. Gordon N, Andrii CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2008; 30: 611–615.
21. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004; 10: 8114–8119.
22. Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 2001; 61: 4066–4071.
23. Escattf F, Vaute O, Chevillard-Briei M, Segui B, Takami Y, Nakayama T et al. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol 2007; 27: 554–567.
24. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafar A et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27: 4784–4795.
25. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274: 1541–1548.
26. Imler M, Thome M, Hahne M, Schneider P, Hofmann K, Steimer V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195.
27. Lavik IN. Regulation of death receptor-induced apoptosis induced via CD95/FAS and other death receptors. Mol Biol 2011; 45: 173–179.
28. Benetou M, Dubaron S, Moreau JF, Taupin JF, Legembre P. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res 2007; 67: 108–115.
29. Bagnoli M, Carevani S, Mezzanarica D. Cellular FLICE-inhibitory protein (c-FLIP) signaling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010; 42: 210–213.
30. Song JH, Tse MC, Belaila A, Phuphanich S, Khuri F, Kneteman NM et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67: 6946–6955.
31. Colgan JEA, Margules DH, Shewach EM, Strober W. Current Protocols in Immunology. In: Coico R: John Wiley & Sons I (ed). Related Isolation Procedures and Functional Assays, vol. 1, 1995.
32. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005; 5: 12.